Sachdev Amit 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Vertex (VRTX) EVP Sachdev Amit Receives 11,749-Share Award
What Happened Sachdev Amit, EVP, Chief Patient & External Affairs Officer at Vertex Pharmaceuticals (VRTX), was awarded a total of 11,749 shares (7,866 + 3,883) on 2026-01-22 as earned performance shares. The shares were reported as acquired at $0 (award/grant), reflecting performance-vested stock units rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-01-22; Form filed 2026-01-26 (reporting period 2026-01-22).
- Award details:
- 7,866 shares (footnote F1) — from a PSU granted 02/01/2023; performance certified 01/22/2026; vesting date 02/13/2026.
- 3,883 shares (footnote F2) — from a PSU granted 02/12/2025; performance certified 01/22/2026; vesting in installments beginning 02/24/2026.
- Acquisition price reported: $0 (stock awarded as compensation). Total shares awarded: 11,749.
- Shares owned after the transaction are not specified in the excerpt provided.
Context These transactions are awards of performance-based shares (code A) that reflect achievement of pre-set goals and will vest on the dates above; they are routine compensation actions, not open-market buying or selling. For retail investors, awards indicate compensation recognition but are not direct buy/sell signals.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-22+7,866→ 67,115 total - Award
Common Stock
[F2]2026-01-22+3,883→ 70,998 total
- 882(indirect: By 401(k))
Common Stock
- 9,301(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
- [F2]Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.